baber/WOPTO huggingface dataset:
Patent BR-PI1007042-B1 (BR)
Title: Trocador de calor
Inventor: STEVEN M WAND
IPC: F25B39/04
Filed: 2010-01-22
Abstract: trocador de calor. a presente invenção refere-se a um trocador de calor (8) com um desempenho ótimo e um método de otimização da performance de um trocador de calor (8). o trocador de calor (8) tem um primeiro duto coletor (24a), um segundo duto coletor (24b) e tubos (14) que se estendem entre eles. os tubos (14) têm pelo menos uma abertura (26) a qual se estende através do comprimento inteiro dos tubos (14). o método pode incluir: o governo da perda de pressão no trocador de calor (8) pela seleção de aberturas de tamanho diferente ou configurações dos tubos (14) dependendo do tipo de refrigerante usado e das propriedades do mesmo; a otimização das dimensões do primeiro duto coletor (24a) e do segundo duto coletor (24b), de modo que a relação de coletor para tamanho de tubo (14) ou coletor para área de seção transversal de abertura (26) de tubo produz baixas perdas de pressão e minimize os efeitos de perda de pressão na combinação de coietor e tubo; e a otimização da relação da capacidade de fluxo em massa dos primeiro e segundo dutos coletores (24a,24b) para a capacidade de fluxo de tubos (14), de modo que o primeiro duto coletor (24a) tenha um efeito de má-distribuição mínimo ou desprezível quando provendo refrigerante para os tubos (14), desse modo se melhorando a desempenho geral do trocador de calor (8).
Patent BR-PI1100943-B1 (BR)
Title: junção de tubos para conexão de um primeiro tubo a um segundo tubo e método para acoplar um primeiro tubo a um segundo tubo de uma forma impermeável a fluidos
Inventor: ALFREDO QUIROGA
IPC: F16L19/10
Filed: 2011-03-25
Abstract: JUNÇÃO DE TUBOS PARA CONEXÃO DE UM PRIMEIRO TUBO A UM SEGUNDO TUBO E MÉTODO PARA ACOPLAR UM PRIMEIRO TUBO A UM SEGUNDO TUBO DE UMA FORMA IMPERMEÁVEL A FLUIDOS. A invenção diz respeito a uma junção de tubos, para conexão de um primeiro tubo a um segundo tubo, compreendendo um elemento pino oco (2) no lado do primeiro tubo, compreendendo um elemento caixa oco (3), que fica, pelo menos parcialmente, circundando o elemento pino (2), e que é conectado a um segundo tubo, em que uni primeiro anel (4) é colocado próximo a uma extremidade do dito elemento pino (2), e um segundo anel (5) é acoplado com o elemento caixa (3), e em que o segundo anel (5) fica em contato axial com o primeiro anel (4), em que o primeiro anel (4) fica em contato axial com o dito elemento caixa (3), em que o segundo anel (5) geralmente se estende do primeiro anel (4), na direção oposta à dita extremidade do elemento pino (2), que fica próxima ao elemento pino (3). A invenção também diz respeito a um método para acoplar, de uma forma impermeável a fluidos, um primeiro tubo a um segundo tubo.
Patent EA-001780-B1 (EA)
Title: Pyridylcarbomoylindoline derivatives as 5-ht2c-receptor antagonists
Inventor: BROMIDGE STEVEN MARK
IPC: A61P43/00
Filed: 1997-06-16
Abstract: 1. A compound of formula (I) or a salt thereof:   wherein: X is CH or N; R<1> is hydrogen or C1-6 alkyl; R<2> and R<3> groups are independently halogen, C1-6 alkyl, or trifluoromethyl. 2. A compound according to claim 1 in which X is CH. 3. A compound according to claim 1 or 2 in which R<1> is methyl. 4. A compound according to any one of claims 1 to 3 in which R<2> is CF3. 5. A compound according to any one of claims 1 to 4 in which R<3> is C1-6 alkyl. 6. A compound according to any one of claims 1 to 5 in which R<3> is methyl. 7. A compound according to claim 1 which is: 5-methyl-6-trifluoromethyl-1-[6-(2-methylpyridin-3-yloxy)-pyridin-3ylcarbamoyl]indoline, 5-methyl-6-trifluoromethyl-1-[6- (2-methylpyridin- 3-yloxy)-pyridazin-3- ylcarbamoyl]indoline, and pharmaceutically acceptable salts thereof. 8. A compound according to claim 1 which is 5-methyl-6-trifluoromethyl-1-[6- (2-methylpyridin-3-yloxy)-pyridin-3-ylcarbamoyl]indoline hydrochloride. 9. A process for preparing a compound according to any one of claims 1 to 6 which comprises reacting a compound of formula (II);   with a compound of formula (III);   in which R<1>, R<2> and R<3> are as defined in formula (I) and A and B have the following meanings: (i) A is -N=C=O and B is hydrogen, (ii) A is -NHCOL and B is hydrogen, (iii) A is -NH2 and B is COL, or (iv) A is halogen and B is -CONH2 wherein L is a leaving group, and thereafter optionally forming a pharmaceutically acceptable salt thereof. 10. A compound according to any one of claims 1 to 8 for use in therapy as 5-HT2C receptor antagonists. 11. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier or excipient. 12. Use of a compound according to any one of claims 1 to 8 for the manufacture of a medicament for the treatment of anxiety andlor depression. 13. A compound of formula (II);   in which R<1> and X are as defined in formula (I) and A is -N=C=O, NHCOL where L i s a leaving group, NH2 or halogen.
Patent EA-002335-B1 (EA)
Title: An electrically operated valve or damper actuator having an electric motor directly coupled to the actuator drive shaft
Inventor: WHITWORTH CHRISPHER JOHN
IPC: H02K7/10
Filed: 1999-04-16
Abstract: 1. An electrically operated actuator for operating a valve or damper having an actuating shaft that has an operational torque requirement greater than 10 Nm, said electrically operated actuator comprising: (i) a housing, (ii) a drive shaft rotatably mounted within the housing and having a first end which extends from the housing for direct coupling to the actuating shaft of the valve or damper, (iii) an electric motor capable of developing a torque greater than 10 Nm axially mounted on the drive shaft, and (iv) means for controlling the operation of the motor. 2. An actuator according to claim 1 wherein the electric motor is a variable speed, permanent magnet, constant torque electric motor. 3. An actuator according to claim 2 wherein the electric motor is a high torque, direct current motor operated by pulse width modulation. 4. An actuator according to claim 3 wherein the electric motor is adapted to provide an infinitely variable output speed of the drive shaft over a predetermined speed range. 5. An actuator according to claim 3 wherein the electric motor is adapted to provide a constant torque over a predetermined speed range. 6. An actuator according to claim 1 wherein the rotor is rotatably mounted on the drive shaft and wherein the actuator further inclues a clutch for coupling the rotor to the drive shaft. 7. An actuator according to claim 6 wherein the clutch inclues a drive sleeve slidably mounted on the drive shaft but not rotatable with respect to the drive shaft, drive pins on the drive sleeve, drive pins on the rotor and spring means for normally biasing the drive sleeve towards the rotor so that the drive pins are engaged. 8. An actuator according to claim 7 and further including cam means adapted to engage the drive sleeve and move the drive sleeve away from the rotor against the action of the spring means to disengage the drive pins. 9. An actuator according to claim 8 wherein the other end of the drive shaft is connected to a hand wheel adapted to rotate the drive shaft when the drive pins are disengaged. 10. An actuator according to claim 1 wherein the means for controlling the operation of the electric motor is a motor drive control comprising circuitry to drive and protect the motor and a human interface control adapted to set the operational parameters of the actuator. 11. An actuator according to claim 10 wherein the control means inclues a microprocessor programmed to allow the operational parameters to be set and to generate an alarm when any setting is exceeded. 12. An actuator according to claim 10 wherein the human interface control allows the operational parameters to be set from a local or remote location.
Patent EA-005532-B1 (EA)
Title: Substituted imidazoles as tafia (active thrombin activatable fibrinolysis inhibitor) inhibitors
Inventor: ALLERTON CHARLOTTE MOIRA NORFO
IPC: A61P37/08
Filed: 2001-08-08
Abstract: The present invention provides compounds of formula (I). These compounds are a class of TAFIa inhibitors, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.
Patent EA-006747-B1 (EA)
Title: Isoxazoline derivatives as anti-depressants
Inventor: ANDRES-GIL JOSE IGNACIO
IPC: A61P25/00
Filed: 2002-02-13
Abstract: The invention concerns substituted isoxazolines derivatives according to Formula (I):wherein X = CH, N-R, S or O, R, Rand Rare certain specific substituents, Pir is an optionally substituted piperidyl or piperazyl radical and Rrepresents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S ; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression and/of anxiety and disorders of body weight. The compounds according to the invention have surprisingly been shown to have a serotonine (5-HT) reuptake inhibitor activity in combination with additional [alpha]2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. Compounds according to the invention are also suitable for treating patients with anxiety disorders and disorders of body weight. The invention also relates to novel combination of substituted isoxazolines derivatives having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.
Patent EA-005959-B1 (EA)
Title: A method for precipitating iron from a zinc sulphate solution as hematite
Inventor: LANTINEN MARKO
IPC: C22B3/44
Filed: 2002-12-03
Abstract: This invention relates to a method for the removal of iron as hematite from a zinc sulphate solution in atmospheric conditions during the electrolytic preparation of zinc. According to the method, the pH of the iron-containing solution is adjusted to a value of at least 2.7, oxygen-containing gas is fed into the solution and part of the hematite thus formed is recirculated to the precipitation stage.
Patent EA-009198-B1 (EA)
Title: SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDON-4-ONE DERIVATIVES
Inventor: LOCHEAD ALISTAIR
IPC: C07D487/04
Filed: 2004-03-19
Abstract: The invention relates to a substituted-pyrimidone derivative represented by formula (I) or a salt thereof, wherein: X represents two hydrogen atom, a sulfur atom, an oxygen atom or a Calkyl group and a hydrogen atom; Y represents a bond, a carbonyl group, a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the rings being optionally substituted; R2 represents a phenyl group or a naphthalene ring; the phenyl group and the naphthalene ring being optionally substituted; R3 represents a hydrogen atom or a Calkyl group; R4 represents a Cperhalogenated alkyl group or a Chalogenated alkyl group; R5 represents a hydrogen atom; a Calkyl group or a halogen atom; n represents 0 to 3; and p+q=0 to 3.The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3beta, such as Alzheimer disease.
Patent EA-013528-B1 (EA)
Title: Method for the treatment of narcotic and alcoholic dependency
Inventor: BORISEVICH IRINA IVANOVNA
IPC: A61M21/00
Filed: 2005-12-14
Abstract: A method for the treatment of narcotic and/or alcoholic dependency is characterized in that prior to prescribing the treatment a structure of a patient's character is additionally studied, for that the patient is accommodated in special milieu for the whole action period, the treatment program is determined based on an amnesia by the results of motivation rate and the structure of a patient's character by forming  individual tasks, the treatment is carried out continuously for at least 3-4 months and at least in two stages, each is divided into steps, at the first stage determined as "motivation", the milieu is formed individually for each patient, the treatment program is determined according to the patient's development from "conception to birth" enabling to isolating and separating healthy part and narcotic and/or alcoholic dependence with subsequent "burial" ritual of personality narcotic and/or alcoholic dependence and "birth" of healthy personality forming a stable motivation to recovery in the patient , and at the second stage determined as "main", the milieu is formed individually or for a group of 2-12 patients, the treatment program is determined  according to the patient's development period from "birth to full age" forming a dependence-free personality, wherein at each stage and step situations are created for a patient to take an independent solution and proper use of acquired habits with subsequent responsibility for own behavior and transfer from the stage to the stage and from step to the step is carried out  after the fulfillment patient's tasks and purposes in accordance with the predetermined treatment program, the results of said tasks and purposes are tested at definite time moments, and by evaluating the results at random time moments by independent experts. The treatment can be also continued at stages "primary social adaptation" and "commune".
Patent EA-013114-B1 (EA)
Title: Method and device for molding cope and drag
Inventor: HIRATA MINORU
IPC: B22C19/04
Filed: 2006-08-08
Abstract: A method and a device for molding a cope and a drag capable of preventing a warpage from occurring on molded cope and drag or a match plate from being damaged. In the method, the match plate (1) is held by upper and lower flasks (2, 3), and upper and lower squeeze means (4, 5) are inserted into the opening parts of the upper and lower flasks without match plate to form cope and drag molding spaces. Next, a foundry sand is filled in these cope and drag molding spaces and the upper and lower squeeze means are advanced to the match plate to squeeze the foundry sand in the cope and drag molding spaces for molding the cope and drag. The method is characterized in that the upper and lower squeeze means are advanced to the match plate while a difference between an upper squeeze force and a lower squeeze force is maintained within a predetermined allowable range.
Patent EA-016693-B1 (EA)
Title: Process and apparatus for producing shaped frozen confections
Inventor: DOEHREN PAUL MICHAEL
IPC: A23P30/20
Filed: 2008-05-13
Abstract: A process for shaping a frozen confectionery product is provided, the process comprising: extruding a frozen confection from a filling means into a cavity defined by a mould block and a base; moving the mould block relative to the base; and removing the frozen confection from the cavity, characterized in that the cross-section of the base, when viewed along the direction of relative motion of the cavity and the cutting means, is not a straight line.
Patent EA-021473-B1 (EA)
Title: Inhaler
Inventor: KAAR SIMON G
IPC: A61M15/00
Filed: 2010-06-08
Abstract: An inhaler (10), such as a breath-actuated metered-dose inhaler, for delivering medicament to a patient. The inhaler (10) comprises a housing for holding the medicament and having an air inlet means (12) and a medicament delivery port which together define an air flow path into which the medicament is dispensed. The air inlet means (12) comprises an array of elongate apertures (24) formed in the housing, the long sides of adjacent apertures (24) facing each other. Each aperture (24) is provided with a respective different opening in an outer surface of the housing. The opening of each aperture (24) extends in two different planes such that, if at least a part of the opening is covered in one of the two different planes during inhalation by the patient, a void space is created between the cover and the aperture (24) so as to provide an air flow path through the void space to the at least one aperture (24).
Patent EA-020617-B1 (EA)
Title: Casb7439 constructs
Inventor: BLAIS NORMAND
IPC: C07K14/47
Filed: 2010-05-25
Abstract: The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and to methods of utilizing the same.
Patent EA-020522-B1 (EA)
Title: Handling device for drill pipes, especially devices known as pipe handlers or top drives with pipe handlers, and operating method therefor
Inventor: HOFSTE BERND
IPC: E21B19/08
Filed: 2010-08-20
Abstract: The invention relates to a handling device for drill pipes (18) and to a so-called top drive (16) gripping said handling device, a so-called pipe handler, having means for detecting a position of elevator equipment (30) gripped by the handling device/pipe handler and for forwarding the associated positional information. The positional information is forwarded from the pipe handler to, for example, the top drive (16) and is converted into an electrical signal for detecting and avoiding possibly critical situations as a result of a position/deflection of the elevator equipment (30).
Patent EA-030710-B1 (EA)
Title: Apparatus for tightening threaded joints
Inventor: RASKA RICHARD J
IPC: B25B23/00
Filed: 2011-02-09
Abstract: According to a first aspect of the invention, provided is a powered tool for reaction-free/reaction-assisted tightening/loosening of a threaded joint in industrial conditions, comprising a motor (102) to generate a rotating force to rotate the threaded joint part being tightened/loosened; an enhancing assembly (200) with an impact mechanism (250) to provide the rotating force for a higher speed and a lower torque mode, including a plurality of impact rotating force transmitting assemblies (251, 252), and with a multiplication mechanism (210) for multiplication of the rotating force to operate in a lower speed and a higher torque mode including a plurality of multiplying, rotating force transmitting assemblies (211, 212, 213), at least one of which being connected, in a working state, to a housing (220) of the enhancing assembly (200); a handle (104) for the operator to hold said housing (220); a reactive mechanism (401) to transfer a reactive force generated on said housing (220) in the lower speed and a higher torque mode to a stationary object; wherein, during the higher speed and lower torque mode, at least two impact rotating force transmitting assemblies (251, 252) can perform impacts; or said housing (220) and at least two multiplying, rotating force transmitting assemblies (211, 212, 213) are stationary, or said housing (220) and at least two multiplying, rotating force transmitting assemblies (211, 212, 213) can rotate jointly, or the housing (220) is stationary and at least two multiplying, rotating force transmitting assemblies (211, 212, 213) can rotate jointly to provide a drive-in effect of the impact mechanism (250); during the lower speed and higher torque mode, at least two multiplying, rotating force transmitting assemblies (211, 212, 213) can be set to rotation relative each other, or at least two impact rotating force transmitting assemblies (251, 252) are stationary, or at least two impact rotating force transmitting assemblies (251, 252) and at least one multiplying, rotating force transmitting assembly (211, 212, 213) can rotate jointly.
Patent EA-028080-B1 (EA)
Title: Mek1 mutation conferring resistance to raf and mek inhibitors
Inventor: GARRAWAY LEVI A
IPC: C12N9/12
Filed: 2011-06-09
Abstract: The invention relates to an isolated nucleic acid molecule encoding a mutant MEK1 protein having MEK1 activity, a vector comprising said nucleic acid molecule, a host cell comprising said vector, a method of producing a mutant MEK1 protein, an isolated mutant MEK1 protein, a method of identifying a subject having cancer, a method of optimizing treatment of a subject.
Patent EA-022365-B1 (EA)
Title: Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
Inventor: WANG WENHUA
IPC: A61K31/7042
Filed: 2011-05-11
Abstract: The present invention relates to formulations including compounds of Formula (I)or a prodrug, or a pharmaceutically acceptable salt thereof.
Patent EA-026950-B1 (EA)
Title: Children cosmetic stick
Inventor: STREKALOV ANTON EVGENIEVICH
IPC: A61K8/97
Filed: 2014-12-15
Abstract: The children cosmetic stick for lips and face can be used as a means for preventing moisture loss by lips and face skin and protecting them against wind and cold (bad weather) made in the shape of a stick. The children cosmetic stick for lips and face includes carnauba wax, candellila wax, bee wax, shea tree seed butter, apricote kernel oil, jojoba oil, almond oil, tocopherol with the following proportion of the components, % by mass: jojoba oil 25-40; almond oil 0.007-0.02; apricote kernel oil 0.007-0.02; shea butter 20-30; tocopherol acetate 0.01-1; bee wax 15-25; candellila wax 7-18; carnauba wax 3-9; fragrance 0.01-0.8.
Patent EA-034390-B1 (EA)
Title: Use of pertuzumab in combination with trastuzumab and chemotherapy for neoadjuvant treatment of early-stage her2-positive breast cancer
Inventor: ALAVATTAM SREEDHARA
IPC: A61K39/395
Filed: 2012-10-11
Abstract: The present invention relates to the use of Pertuzumab in combination with Trastuzumab and carboplatin-based chemotherapy comprising Docetaxel and Carboplatin for the neoadjuvant treatment of early-stage HER2-positive breast cancer in a patient, wherein the early-stage HER2-positive breast cancer does not spread beyond the breast or the axillary lymph nodes, and wherein carboplatin-based chemotherapy comprisesg Docetaxel and Carboplatin.
Patent EA-028085-B1 (EA)
Title: Carbamate compounds and use thereof
Inventor: CISAR JUSTIN S
IPC: C07D203/20
Filed: 2013-01-07
Abstract: This invention provides compounds and compositions described by formulawhich may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, and pharmaceutical compositions that include disclosed compounds as at least one active agent.
Patent EA-025323-B1 (EA)
Title: Aqueous hard surface cleaner based on terpenes and fatty acid derivatives
Inventor: BROWN AARON
IPC: C11D1/04
Filed: 2013-04-12
Abstract: An aqueous hard surface cleaner composition useful for removing permanent ink is disclosed. The composition comprises 75 to 99 wt.% of water; 0.1 to 5 wt.% of a monoterpene; 0.1 to 5 wt.% of a C-Cfatty acid derivative; and 0.1 to 5 wt.% of one or more surfactants. The fatty acid derivative is selected from N,N-dialkyl amides, N,N-dialkyl esteramines, and N,N-dialkyl amidoamines. Preferably, a base such as sodium carbonate or monoethanolamine is also included. The invention includes concentrates comprising the non-aqueous components recited above, as well as other applications for the cleaners and concentrates such as graffiti removers and permanent ink erasers. The combination of a monoterpene and certain fatty acid derivatives, especially fatty N,N-dialkyl amides, unexpectedly enables even dilute aqueous compositions to rapidly decolorize black permanent marker from hard, non-porous surfaces.
Patent EA-028848-B1 (EA)
Title: Ophthalmic solution comprising diquafosol
Inventor: SAKATANI AKIKO
IPC: A61P27/02
Filed: 2013-03-25
Abstract: The present invention relates to a method for reducing eye irritation caused by an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1 to 10% (w/v), by adding ethylenediaminetetraacetic acid or a salt thereof at a concentration of 0.0001 to 1% (w/v) to the aqueous ophthalmic solution.